Development of Sang-35: A cyclosporine formulation bioequivalent to Neoral

Clinical Transplantation

Volumn 12, Issue 6, 1998, Pages 518-524

  First, M Roy ^a   Alloway, Rita ^b   Schroeder, Timothy J ^a,c  

^a UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c GENZYME CORPORATION   (United States)

Author keywords

Bioequivalence; Cyclosporine; Cyclosporine formulation; Kidney transplantation; Neoral; Sandimmune; Sang 35; Switchability

Indexed keywords

CYCLOSPORIN; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG FORMULATION; FEMALE; GRAFT REJECTION; HUMAN; HUMAN EXPERIMENT; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; LIPID DIET; MALE; MICROEMULSION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VOLUNTEER;

ADMINISTRATION, ORAL; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; CYCLOSPORINE; DOSAGE FORMS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; THERAPEUTIC EQUIVALENCY;

EID: 0031754486     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. KOVARIK JM, MUELLER EA, NIESE D. Clinical development of a cyclosporine microemulsion in transplantation. Ther Drug Monit 1996: 18: 429.
2. KAHAN BD, WELSH M, SCHOENBERG L, RUTZKY LP, KATZ SM, URBAUER DL, VAN BUREN CT. Variable oral absorption of cyclosporine. Transplantation 1996: 62: 599.
3. KAHAN BD, WELSH M, RUTZKY LP. Challenges in cyclosporine therapy: the role of therapeutic monitoring by area under the curve monitoring. Ther Drug Monit 1995: 17: 621.
4. OLYAEI AJ, DE MATTOS AM, BENNETT WM. Switching between cyclosporin formulations. What are the risks? Drug Safety 1997: 16: 366.
5. VONDERSCHER J, MEINZER A. Rationale for the development of Sandimmune Neoral. Transplant Proc 1994: 26: 2925.
6. NOBLE S, MARKHAM A. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral). Drugs 1995: 50: 924.
7. JOHNSTON A, KEOWN PA, HOLT DW. Simple bioequivalence criteria: Are they relevant for critical dose drugs? Experience gained from cyclosporine. Ther Drug Monit 1997: 19: 375.
8. PATNAIK RN, LESKO LJ, CHEN ML, WILLIAMS RL, THE FDA INDIVIDUAL BIOEQUIVALENCE WORKING GROUP. Individual bioequivalence. New concepts in the statistical assessment of bioequivalence matrices. Clin Pharmacokinet 1997: 33: 1.
9. FOOD AND DRUG ADMINISTRATION. Bioavailability and bioequivalence requirements. Federal Register 1992: 17997.
10. DEPARTMENT OF HEALTH AND HUMAN SERVICES, FOOD AND DRUG ADMINISTRATION, CENTER FOR DRUG EVALUATION AND RESEARCH (CDER). Guidance for industry. In vivo bioequivalence studies based on population and individual bioequivalence approaches. Version October 1997.
11. SAUTER R, STEINIJANS VW, DILETTI T, BÖHM A, SCHULZ HU. Presentation of results from bioequivalence studies. Int J Pharmacol Ther Toxicol 1992: 30: 233.
12. KOVARIK JM, MUELLER EA, VAN BREE JB, FLUCKIGER SS, LANGE H, SCHMIDT B, BOESKEN WH, LISON AE, KUTZ K. Cyclosporine pharmacokinetics and variability from a microemulsion formulation: a multicenter investigation in kidney transplant patients. Transplantation 1994: 58: 658.
13. ASPESLET LJ, LE GATT DF, MURPHY G, YATSCOFF RW. Effect of assay methodology on pharmacokinetic differences between cyclosporine Neoral and Sandimmune formulations. Clin Chem 1997: 43: 108.
14. BENET LZ, GOYAN JE. Bioequivalence and narrow therapeutic index drugs. Pharmacotherapy 1995: 15: 433.